Common Contracts
6 similar Sales Agreement contracts by Agile Therapeutics Inc, Allovir, Inc., Centessa Pharmaceuticals PLC, others
MIRUM PHARMACEUTICALS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • November 2nd, 2023 • Mirum Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (each, an “Agent” and together, the “Agents”), as follows:
CENTESSA PHARMACEUTICALS PLC $125,000,000 American Depositary Shares Representing $125,000,000 Ordinary Shares, Nominal Value £0.002 Per Share SALES AGREEMENTSales Agreement • January 27th, 2023 • Centessa Pharmaceuticals PLC • Pharmaceutical preparations • New York
Centessa Pharmaceuticals plc, a public limited company incorporated under the laws of England and Wales with registered number 12973576 (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows:
PHARVARIS N.V. Ordinary Shares (nominal value of €0.12 per share) SALES AGREEMENTSales Agreement • March 2nd, 2022 • Pharvaris N.V. • Pharmaceutical preparations • New York
Pharvaris N.V., a public limited liability company (naamloze vennootschap) (the “Company”), confirms its agreement (this “Agreement”) with SVB Securities LLC (the “Agent”), as follows:
AGILE THERAPEUTICS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • January 10th, 2022 • Agile Therapeutics Inc • Pharmaceutical preparations • New York
Agile Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. ( “Cantor”) and H.C. Wainwright & Co., LLC (“HCW”; each of Cantor and HCW individually an “Agent” and together, the “Agents”), as follows:
ALLOVIR, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENTSales Agreement • August 6th, 2021 • Allovir, Inc. • Biological products, (no disgnostic substances) • New York
Allovir, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows:
STOKE THERAPEUTICS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • July 10th, 2020 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • New York
Stoke Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. and Stifel, Nicolaus & Company, Incorporated (each, an “Agent” and together, the “Agents”), as follows:
